R&D, RISK, AND PERFORMANCE IN THE SPANISH PHARMACEUTICAL INDUSTRY: A STRATEGIC GROUP ANALYSIS

Abstract

This paper shows an analysis of strategic groups in the Spanish pharmaceutical industry. The first results reveal that differences between company performance and strategic groups do not exist. However, taking into account the innovative process in the pharmaceutical industry, when considering the risk-adjusted results we have confirmed the existence of differences among the strategic groups for some of the used indicators. The combination of radical and low-impact innovations, production for third parties, and commercialization under licenses can offer a better performance than other groups focused exclusively in innovation or in specific market segments.

An institutional theory of quality outcomes in strategic supply chain partnership

“…This study also contributes to the existing body of knowledge in strategic groups through addressing quality. Previous studies on strategic groups have limited their analysis to performance measures such as financial performance or market share (Short et al, 2007;Uárez-Serrano and Piña-Mavarez, 2011). By focusing on quality measures, the paper extends the existing body of knowledge in strategic group performance.…”

French Pharmaceutical Strategic Clusters: A Hybrid Inducto‐deductive Framework for Visual Analysis of Competitive Spaces

“…US studies report conflicting results regarding the link between performance and strategic group membership (Cool, 1985;Cool and Schendel, 1987;Martens, 1988;Bogner, 1991;Bogner et al, 1996;Guedri, 1998). In the studies which have measured the aspects of strategic group performance in the pharmaceutical industry, a number of common points were identified (Cool, 1985;Cool andSchendel, 1987, 1988;Martens, 1988;Bogner, 1991;Voyer, 1993;Cool et al, 1994;Guedri, 1998;Suárez et al, 2011). First, in all cases, several relatively stable strategic groups were identified despite significant changes recorded over a given period of time.…”